Nanovi was founded in 2012 with the aim of raising radiotherapy standards without changing current routines and equipment. The idea arose from a real medical need for better guidance of radiation treatment, which the founders believed could be solved by advanced biomaterials.
The concepts and technologies matured in 2013-2014 in parallel with the development of the commercial strategy for Nanovi.
Radiotherapy is the most cost-effective treatment modality for many cancers, and nearly two-thirds of all cancer patients receive radiotherapy as a part of their treatment.
The main challenge in radiotherapy is to administer a sufficiently high dose to the cancer cells with minimal damage to the surrounding healthy tissue. Tumor motion and inadequate patient set-up are two important factors, which constitute this challenge.
Image-guided radiation therapy (IGRT) is a method of radiation therapy that incorporates imaging techniques during each treatment session. IGRT is employed to mitigate errors derived from tumor motion and inadequate patient set-up. The benefits of IGRT includes:
- Accurate delivery of radiation
- Improved definition, localization and monitoring of tumor position, size and shape before and during treatment
- The possibility of higher, targeted radiation dosage to improve tumor control
- Decreased radiation exposure to normal tissue surrounding the tumor
IGRT requires use of frequent imaging and good visibility of tumors and organs at risks. However, soft tissue targets are most often not visible on x-ray images due to a very low tumor to tissue contrast ratio. Hence, soft tissue markers are placed in proximity to the tumor to work as an accurate surrogate.
BioXmark® has the potential to improve radiotherapy precision and therapy outcome.